Aardvark Therapeutics Inc (AARD) Stock Price, Quote & News

Company Profile

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 225 7696

Website: aardvarktherapeutics.com

Address:

4370 La Jolla Village Drive, Suite 1050, San Diego, United States

Biotechnicity Aug. 20 at 7:28 AM

$AARD Don’t hold a position here but want to voice a minority opinion holding that SAE’s in healthy subjects is Bullsh*t given that already compromised Prader-Willi patients might not experience the same response. It’s entirely possible that patients with already compromised CVS may, in fact, respond differently. I’m well aware of the historical precedent of caution with respect to healthy patients but scraping a study on that axiom alone seems precipitous. Aardvark will launch the Phase-3 again.

0 · Reply

focafoca99 Aug. 17 at 6:25 PM

$AARD announced a securities class-action deadline for investors on Oct 13.

0 · Reply

MoneyFairyBlessings Aug. 11 at 3:29 PM

$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.

0 · Reply

55X_ROI_Q1_2026 Aug. 2 at 7:52 AM

$AARD $SLS @jfais is a pos short scumbag. $XBI said to sell SlS short +400% ago. "Through my years of working in cancer immunotherapy, I have witnessed great advances in the field, and I believe SELLAS is on the verge of such an advance. I have been impressed with the significant potential of the Company's lead product, galinpepimut-S, to successfully treat hematological and solid malignancies through a unique approach of peptide-based immunization against the WT1 oncoprotein," stated Dr. Weber. "I am excited to join the other scientists on the Company's SAB and offer the insights that I have in the area of oncoimmunology research and development.

0 · Reply

eyepeefreeley Aug. 1 at 9:49 PM

$AARD $SLS

0 · Reply

EddieH2020 Aug. 1 at 9:30 PM

$SLS Here is the link for handy reference as we go up: https://stocktwits.com/JFais/message/634612371 SLS is gonna send you and Seedy back to Peru 🤣 @OnTheBalance 😋 $XBI $SPY

1 · Reply

Yashinvest Jul. 28 at 7:09 AM

$AARD Daily chart, price doubling potential

0 · Reply

jumanah1212 Jul. 27 at 7:40 PM

$AARD head and shoulders 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jul. 23 at 2:51 PM

$AARD Double Bottom pattern: Suggests a potential bullish reversal (strong support at the two bottoms) Nearby resistance: $7.90, $10.00💸💸🚀🚀

0 · Reply

StockScanners Jul. 14 at 6:01 AM

$AARD reached 7.92

0 · Reply

AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

2026-08-17T11:09:12.000Z - 4 days ago

Aardvark Therapeutics reports Q2 EPS (66c), consensus (88c)

Aug 14, 2026, 12:00 PM EDT - 7 days ago

Aardvark Therapeutics Transcript: AGM 2026

Aug 11, 2026, 4:53 PM EDT - 10 days ago

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Aug 11, 2026, 4:00 PM EDT - 10 days ago

Aardvark Therapeutics Earnings release: Q2 2026

Aug 11, 2026, 4:00 PM EDT - 10 days ago

Aardvark Therapeutics Quarterly report: Q2 2026

Jul 10, 2026, 8:00 AM EDT - 6 weeks ago

Aardvark Therapeutics Proxy statement: Proxy filing

Jun 29, 2026, 8:00 AM EDT - 7 weeks ago

Aardvark Therapeutics Proxy statement: Proxy filing

Jun 25, 2026, 9:00 AM EDT - 2 months ago

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS

2026-05-15T20:00:16.000Z - 3 months ago

Aardvark Therapeutics downgraded to Underperform from Buy at BofA

NBIX RYTM

2026-05-15T15:16:12.000Z - 3 months ago

Aardvark Therapeutics price target lowered to $7 from $8 at B. Riley

2026-05-15T14:43:58.000Z - 3 months ago

Aardvark Therapeutics Inc trading halted, volatility trading pause

2026-05-15T14:36:56.000Z - 3 months ago

Aardvark Therapeutics Inc trading resumes

2026-05-15T13:30:50.000Z - 3 months ago

Aardvark Therapeutics downgraded to Neutral from Buy at BTIG

2026-05-15T08:45:48.000Z - 3 months ago

Aardvark downgraded to Underweight from Equal Weight at Morgan Stanley

2026-05-14T22:08:33.000Z - 3 months ago

Aardvark Therapeutics announces FDA clinical hold on ARD-101

May 14, 2026, 4:53 PM EDT - 3 months ago

FDA places full clinical hold on Aardvark's drug for extreme hunger in Prader-Willi syndrome

May 14, 2026, 4:01 PM EDT - 3 months ago

Aardvark Therapeutics Plans to Unblind HERO and OLE Data to Inform Path Forward Following FDA Clinical Hold

2026-05-10T14:36:28.000Z - 3 months ago

Aardvark Therapeutics price target lowered to $18 from $20 at BofA

2026-05-07T19:19:23.000Z - 3 months ago

Aardvark Therapeutics reports Q1 EPS (99c), consensus (91c)

May 7, 2026, 8:00 AM EDT - 3 months ago

Aardvark Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 7:00 AM EDT - 3 months ago

Aardvark Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 3 months ago

Aardvark Therapeutics Earnings release: Q1 2026

2026-03-24T12:42:34.000Z - 5 months ago

Aardvark Therapeutics price target lowered to $8 from $32 at B. Riley

2026-03-23T21:15:11.000Z - 5 months ago

Aardvark Therapeutics files $400M mixed securities shelf

2026-03-23T20:16:52.000Z - 5 months ago

Aardvark Therapeutics reports Q4 EPS (81c), consensus (83c)

Mar 23, 2026, 4:05 PM EDT - 5 months ago

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Aardvark Therapeutics Annual report: Q4 2025

Mar 23, 2026, 4:00 PM EDT - 5 months ago

Aardvark Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Aardvark Therapeutics Registration statement: Registration filing

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm

2026-03-02T14:01:55.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $45 from $50 at Cantor Fitzgerald

2026-03-02T12:51:55.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $9 from $26 at BTIG

2026-03-02T12:43:32.000Z - 6 months ago

Aardvark Therapeutics price target lowered to $21 from $35 at Oppenheimer

Feb 27, 2026, 4:05 PM EST - 6 months ago

Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome

Feb 13, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 12, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer

Feb 12, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces Leadership Appointments

Feb 10, 2026, 8:00 AM EST - 6 months ago

Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome

Dec 10, 2025, 4:05 PM EST - 9 months ago

Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome

Dec 4, 2025, 11:15 AM EST - 9 months ago

Aardvark Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 8:00 AM EST - 9 months ago

Aardvark Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 4:05 PM EST - 9 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Nov 24, 2025, 3:00 PM EST - 9 months ago

Aardvark Therapeutics Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit

Nov 13, 2025, 4:05 PM EST - 10 months ago

Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Nov 13, 2025, 4:00 PM EST - 10 months ago

Aardvark Therapeutics Quarterly report: Q3 2025

Nov 13, 2025, 4:00 PM EST - 10 months ago

Aardvark Therapeutics Earnings release: Q3 2025

Nov 11, 2025, 4:40 PM EST - 10 months ago

Aardvark Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 4:05 PM EST - 10 months ago

Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Nov 5, 2025, 5:00 PM EST - 10 months ago

Aardvark Therapeutics Transcript: Study Update

Nov 5, 2025, 5:00 PM EST - 10 months ago

Aardvark Therapeutics Press release: Study Update

Nov 4, 2025, 12:00 PM EST - 10 months ago

Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025

Nov 3, 2025, 5:55 PM EST - 10 months ago

Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Nov 3, 2025, 8:00 AM EST - 10 months ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in November

Oct 22, 2025, 8:00 AM EDT - 10 months ago

Aardvark Therapeutics to Present Data on Pipeline Programs at Upcoming ObesityWeek

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

Sep 30, 2025, 9:00 AM EDT - 11 months ago

Aardvark Therapeutics Transcript: Stifel Virtual Cardiometabolic Forum

Sep 23, 2025, 4:05 PM EDT - 11 months ago

Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 8, 2025, 7:00 AM EDT - 1 year ago

Aardvark Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 3, 2025, 11:30 AM EDT - 1 year ago

Aardvark Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:00 AM EDT - 1 year ago

Aardvark Therapeutics Slides: Corporate Presentation

Aug 27, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in September

Aug 13, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Second Quarter 2025 Financial Results and Provides Pipeline and Business Updates

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Aardvark Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 6:00 PM EDT - 1 year ago

Aardvark Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination, and Effective Maintenance Following Discontinuation of GLP-1RA Therapy

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference

May 21, 2025, 2:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 3:30 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Bolsters Leadership Team with Strategic Hires Across Scientific, Commercial, Regulatory and Legal Functions

May 15, 2025, 12:35 PM EDT - 1 year ago

Aardvark Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 14, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 7, 2025, 4:05 PM EDT - 1 year ago

Aardvark Therapeutics to Present at Upcoming Investor Conferences in May

Mar 31, 2025, 4:10 PM EDT - 1 year ago

Aardvark Therapeutics Reports Full Year 2024 Financial Results and Provides Business Highlights

Feb 12, 2025, 10:38 PM EST - 1 year ago

Aardvark Therapeutics Announces Pricing of Initial Public Offering

Biotechnicity Aug. 20 at 7:28 AM

0 · Reply

focafoca99 Aug. 17 at 6:25 PM

$AARD announced a securities class-action deadline for investors on Oct 13.

0 · Reply

MoneyFairyBlessings Aug. 11 at 3:29 PM

$AARD Very bullish here. The volume is impressive considering it does not normally have any volume.

0 · Reply

55X_ROI_Q1_2026 Aug. 2 at 7:52 AM

0 · Reply

eyepeefreeley Aug. 1 at 9:49 PM

$AARD $SLS

0 · Reply

EddieH2020 Aug. 1 at 9:30 PM

$SLS Here is the link for handy reference as we go up: https://stocktwits.com/JFais/message/634612371 SLS is gonna send you and Seedy back to Peru 🤣 @OnTheBalance 😋 $XBI $SPY

1 · Reply

Yashinvest Jul. 28 at 7:09 AM

$AARD Daily chart, price doubling potential

0 · Reply

jumanah1212 Jul. 27 at 7:40 PM

$AARD head and shoulders 💸💸🚀🚀🚀🚀

0 · Reply

jumanah1212 Jul. 23 at 2:51 PM

$AARD Double Bottom pattern: Suggests a potential bullish reversal (strong support at the two bottoms) Nearby resistance: $7.90, $10.00💸💸🚀🚀

0 · Reply

StockScanners Jul. 14 at 6:01 AM

$AARD reached 7.92